Brokerages Set Zura Bio Limited (NASDAQ:ZURA) Price Target at $15.80

Zura Bio Limited (NASDAQ:ZURA) has received an average recommendation of “Buy” from the seven analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have covered the stock in the last year is $15.80.

Several research firms recently issued reports on ZURA. Chardan Capital dropped their price objective on Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 8th. HC Wainwright restated a “neutral” rating and set a $5.00 price target on shares of Zura Bio in a research report on Tuesday, December 24th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a report on Wednesday, December 11th. Leerink Partners started coverage on Zura Bio in a report on Monday, November 4th. They set an “outperform” rating and a $15.00 price target on the stock. Finally, Leerink Partnrs raised Zura Bio to a “strong-buy” rating in a research report on Monday, November 4th.

Zura Bio Price Performance

Shares of Zura Bio stock opened at $1.79 on Friday. Zura Bio has a 52 week low of $1.75 and a 52 week high of $6.35. The business has a 50 day moving average price of $2.57 and a 200-day moving average price of $3.48.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). As a group, equities research analysts expect that Zura Bio will post -0.65 EPS for the current year.

Insider Buying and Selling at Zura Bio

In related news, Director Parvinder Thiara sold 1,001,633 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $2.73, for a total value of $2,734,458.09. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 22.10% of the company’s stock.

Institutional Trading of Zura Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Zura Bio in the 3rd quarter worth about $46,000. AQR Capital Management LLC purchased a new position in shares of Zura Bio during the second quarter worth approximately $43,000. SG Americas Securities LLC purchased a new position in shares of Zura Bio during the third quarter worth approximately $62,000. Renaissance Technologies LLC increased its position in shares of Zura Bio by 51.3% during the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after acquiring an additional 5,900 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Zura Bio during the third quarter worth approximately $71,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.